Boston Scientific accounts are for healthcare professionals only.
Dosimetric outcomes
| Conventional fractionation (78 Gy/39 fractions) | |||||
| Pts | rV75 | rV70 | rV60 | rV50 | |
| All | 16 | 0.84% (0-2.7) | 2.25% (0-4.7) | 5.61% (1.7-9.5) | 10.5% (2.39-15.2) |
| P + SV | 4 | 0.75% (0.06-1.77) | 2% (0.75-4.4) | 5.47% (2.5-9.5) | 10.1% (6.4-15.2) |
| P + SV + Lns | 12 | 0.87% (0-2.7%) | 2.3% (0-4.7) | 5.66% (1.7-8.9) | 10.7% (2.3-14.9) |
| P + SV (IMRT) | 2 | 0.58% (0.06-1.1) | 1.61% (0.93-2.3) | 4.95% (4.5-5.4) | 9.45% (9.4-9.5) |
| P + SV (PT) | 2 | 0.93% (0.09-1.77) | 2.57% (0.75-4.4) | 6% (2.5-9.5) | 10.8% (6.4-15.2) |
| Moderate hypofractionation (70 Gy/28 fractions) | |||||
| Pts | rV65 | rV63 | rV60 | rV50 | |
| All P + SV | 17 | 1.67% (0-5.8) | 2.3% (0.1-6.7) | 3.4% (0.4-9.6) | 8.6% (3.3-15.7) |
| P + SV (IMRT) | 9 | 1.16% (0-4.6) | 1.65% (0.1-5.8) | 2.5% (0.3-7.8) | 6.9% (2.46-15) |
| P + SV (PT) | 8 | 2.24% (0.7-5.8) | 3.1% (1.3-6.7) | 4.48% (2.4-9.6) | 10.5% (4.9-15.7) |
Abbreviations: IMRT = intensity modulated radiation therapy; (P + SV) = prostate plus seminal vesicles; (P + SV + Lns) = prostate plus seminal vesicles plus lymph nodes; PT = proton therapy; Pts = patients.
Conventional fractionation (78 Gy/39 fractions)
All patients (n=16)
Mean value and range, rV75 = 0.84% (range, 0 – 2.7), rV70 = 2.25% (range, 0 – 4.7), rV60 = 5.61% (range, 1.7 – 9.5), rV50 = 10.5% (range, 2.39 – 15.2)
Moderate hypofractionation (70 Gy/28 fractions)
All P + SV (n=17)
Mean value and range, rV65 = 1.67% (range, 0 – 5.8), rV63 = 2.3% (range, 0.1 – 6.7), rV60 = 3.4% (range, 0.4 – 9.6), rV50 = 8.6% (range, 3.3 – 15.7)
“Hydrogel placement is feasible in large glands >80cc, even when including a subgroup of patients with prostates >100cc (100.1–186.6 cc) with very favorable dosimetric outcomes which are in line with benchmark published results with smaller glands.”
Reference
- Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–977.
78Gy over 39 fractions was not the method used in the SpaceOAR™ Hydrogel single-blind Phase III trial performed to evaluate dosimetric and clinical effects of SpaceOAR Hydrogel. IG-IMRT delivered at 79.2 Gy in 1.8-Gy fractions was the method used.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
The content of this article/publication is under the sole responsibility of its author/publisher and does not represent the opinion of BSC.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.